FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099682243> ?p ?o ?g. }

• W2099682243 endingPage "195" @default.
• W2099682243 startingPage "189" @default.
• W2099682243 abstract "Cisplatin-based chemotherapy is considered to be a standard treatment in patients with relapsed or extensive-disease (ED) small-cell lung cancer (SCLC), the survival benefit remains modest. Relapsed or ED-SCLC patients were enrolled. Topotecan and amrubicin were administered on Days 1-5 and on Days 3-5, respectively. Nine patients received a total of 24 cycles. Since all three patients experienced dose-limiting toxicity (grade 4 neutropenia lasting for more than 4 days, grade 3 febrile neutropenia, and grade 4 thrombocytopenia) at the third dose level (topotecan: 0.75 mg/m2, amrubicin 40 mg/m2), the maximum tolerated dose was determined to be this dose level. Objective response was observed in six patients (67%). The maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC) of amrubicin increased in a dose-dependent manner. Amrubicin did not influence the pharmacokinetics of topotecan. The Cmax and AUC of amrubicin were correlated with the duration of grade 4 neutropenia. The mean Cmax of topotecan on day 2 in responders (22.9+/-3.6) was significantly higher than that in non-responders (10.9+/-0.4). This phase I study showed the safety and activity of two-drug combination of amrubicin and topotecan in patients with relapsed or ED-SCLC." @default.
• W2099682243 created "2016-06-24" @default.
• W2099682243 creator A5000588868 @default.
• W2099682243 creator A5001897650 @default.
• W2099682243 creator A5006348007 @default.
• W2099682243 creator A5007888883 @default.
• W2099682243 creator A5039723911 @default.
• W2099682243 creator A5042110139 @default.
• W2099682243 creator A5047834232 @default.
• W2099682243 creator A5051708420 @default.
• W2099682243 creator A5052312623 @default.
• W2099682243 creator A5062920555 @default.
• W2099682243 creator A5066700160 @default.
• W2099682243 creator A5070015883 @default.
• W2099682243 creator A5081173458 @default.
• W2099682243 date "2006-08-01" @default.
• W2099682243 modified "2023-09-23" @default.
• W2099682243 title "A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer" @default.
• W2099682243 cites W1605124616 @default.
• W2099682243 cites W1891874310 @default.
• W2099682243 cites W1905197404 @default.
• W2099682243 cites W1952453258 @default.
• W2099682243 cites W1959233016 @default.
• W2099682243 cites W1993312546 @default.
• W2099682243 cites W2037830308 @default.
• W2099682243 cites W2054837357 @default.
• W2099682243 cites W2056422898 @default.
• W2099682243 cites W2057331147 @default.
• W2099682243 cites W2060171352 @default.
• W2099682243 cites W2073683299 @default.
• W2099682243 cites W2083479855 @default.
• W2099682243 cites W2108882850 @default.
• W2099682243 cites W2139248078 @default.
• W2099682243 cites W2150125341 @default.
• W2099682243 cites W2170524710 @default.
• W2099682243 cites W2260360964 @default.
• W2099682243 cites W2262742090 @default.
• W2099682243 doi "https://doi.org/10.1016/j.lungcan.2006.05.008" @default.
• W2099682243 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16806573" @default.
• W2099682243 hasPublicationYear "2006" @default.
• W2099682243 type Work @default.
• W2099682243 sameAs 2099682243 @default.
• W2099682243 citedByCount "11" @default.
• W2099682243 countsByYear W20996822432012 @default.
• W2099682243 countsByYear W20996822432013 @default.
• W2099682243 crossrefType "journal-article" @default.
• W2099682243 hasAuthorship W2099682243A5000588868 @default.
• W2099682243 hasAuthorship W2099682243A5001897650 @default.
• W2099682243 hasAuthorship W2099682243A5006348007 @default.
• W2099682243 hasAuthorship W2099682243A5007888883 @default.
• W2099682243 hasAuthorship W2099682243A5039723911 @default.
• W2099682243 hasAuthorship W2099682243A5042110139 @default.
• W2099682243 hasAuthorship W2099682243A5047834232 @default.
• W2099682243 hasAuthorship W2099682243A5051708420 @default.
• W2099682243 hasAuthorship W2099682243A5052312623 @default.
• W2099682243 hasAuthorship W2099682243A5062920555 @default.
• W2099682243 hasAuthorship W2099682243A5066700160 @default.
• W2099682243 hasAuthorship W2099682243A5070015883 @default.
• W2099682243 hasAuthorship W2099682243A5081173458 @default.
• W2099682243 hasConcept C112705442 @default.
• W2099682243 hasConcept C126322002 @default.
• W2099682243 hasConcept C143998085 @default.
• W2099682243 hasConcept C22979827 @default.
• W2099682243 hasConcept C2776256026 @default.
• W2099682243 hasConcept C2776694085 @default.
• W2099682243 hasConcept C2777063308 @default.
• W2099682243 hasConcept C2778850193 @default.
• W2099682243 hasConcept C2781209748 @default.
• W2099682243 hasConcept C71924100 @default.
• W2099682243 hasConcept C90924648 @default.
• W2099682243 hasConcept C98274493 @default.
• W2099682243 hasConceptScore W2099682243C112705442 @default.
• W2099682243 hasConceptScore W2099682243C126322002 @default.
• W2099682243 hasConceptScore W2099682243C143998085 @default.
• W2099682243 hasConceptScore W2099682243C22979827 @default.
• W2099682243 hasConceptScore W2099682243C2776256026 @default.
• W2099682243 hasConceptScore W2099682243C2776694085 @default.
• W2099682243 hasConceptScore W2099682243C2777063308 @default.
• W2099682243 hasConceptScore W2099682243C2778850193 @default.
• W2099682243 hasConceptScore W2099682243C2781209748 @default.
• W2099682243 hasConceptScore W2099682243C71924100 @default.
• W2099682243 hasConceptScore W2099682243C90924648 @default.
• W2099682243 hasConceptScore W2099682243C98274493 @default.
• W2099682243 hasIssue "2" @default.
• W2099682243 hasLocation W20996822431 @default.
• W2099682243 hasLocation W20996822432 @default.
• W2099682243 hasOpenAccess W2099682243 @default.
• W2099682243 hasPrimaryLocation W20996822431 @default.
• W2099682243 hasRelatedWork W2010935911 @default.
• W2099682243 hasRelatedWork W2033630586 @default.
• W2099682243 hasRelatedWork W2090706904 @default.
• W2099682243 hasRelatedWork W2099682243 @default.
• W2099682243 hasRelatedWork W2370929226 @default.
• W2099682243 hasRelatedWork W2379280247 @default.
• W2099682243 hasRelatedWork W2766550598 @default.
• W2099682243 hasRelatedWork W2942467058 @default.
• W2099682243 hasRelatedWork W3018168093 @default.
• W2099682243 hasRelatedWork W3122926187 @default.

• next